Development of HBs-L based vaccine against Hepatitis B virus

2022 Fiscal Year Final Research Report

• Project/Area Number: 19K16680
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 49060:Virology-related
• Research Institution: Tokyo Metropolitan Institute of Medical Science
• Principal Investigator: SANADA Takahiro 公益財団法人東京都医学総合研究所, 疾患制御研究分野, 主任研究員 (60721272)
• Project Period (FY): 2019-04-01 – 2023-03-31
• Keywords: HBV / B型肝炎 / ワクチン / HBs-L / 経鼻免疫

Outline of Final Research Achievements

To enhance the immunogenicity of HBs-L, HBs-L hybrid (HBs-Lh) protein composed of two genotypes was evaluated. Antibody level induced by HBs-Lh immunization showed high against not only S, but also pre-S1 and pre-S2 domians. Additionally, HBs-Lh immunization induced significantly stronger cross-reactive neutralizing antibodies compared to HBs-S or HBs-L of each genotype.These findings suggest that HBs-Lh could be a candidate of prophylactic HBV vaccine.

Free Research Field

ウイルス学

Academic Significance and Societal Importance of the Research Achievements

本研究によって、L抗原、さらにはLh抗原が現行ワクチンで使用されているS抗原よりも強い免疫原性を有していることが明らかとなった。特に、Lh抗原はいずれの遺伝子型に対しても強い中和抗体誘導能を示しており、本研究を進めることで、新規ワクチン開発へと繋がることが期待される。